Significantly inhibited tumor development (tumor growth and weight) and a lower proportion of CD206+ protumor TAMs was observed in the macrophagic-specific S100A4-KO animals and in the animals treated with PPAR-γ inhibitor compared with control animals (figure 6H, I, J and online supplemental figure 12A, B), in which no body weight change was observed (online supplemental figure 12C, D). Here, S100A4 is linked to neoplasm.